## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

## Listing of Claims:

- 1.-22. (Canceled)
- 23. (Currently Amended) The method of manufacturing A process for the preparation of 7-ethyl-10-hydroxy-camptothecin of formula I

eharacterized in that comprising oxidizing 7-cthyl-1,2,6,7-terahydrocamptothecin tetrahydrocamptothecin of formula IV

is-oxidized with iodobenzene diacetate in acetic acid and in the presence of water under the conditions consisting in that iodobenzene diacetate is used in an amount of 0.99 to 1.85 mol per 1 mol of 7-ethyl-1,2,6,7 tetrahydrocamptothecin, acetic acid is used in an amount of 668 to 1001 mol per 1 mol of 7-ethyl-1,2,6,7 tetrahydrocamptothecin and the oxidation is carried out at a

temperature from 15 to 30°C for 5 to 30 minutes. water, wherein the amount of acetic acid is 668 to 1001 mol per 1 mol of 7-ethyl-1,2,6,7-tetrahydrocamptothecin or 1130 mol per 1 mol of 7-ethyl-1,2,6,7-tetrahydrocamptothecin, and the oxidation is carried out for 5 to 30 minutes.

24. (Currently Amended) The methodprocess according to claim 23, eharacterized in that wherein the starting 7-ethyl-1,2,6,7-tetrahydrocamptothecin is obtained by hydrogenation of 7-ethylcamptothecin of formula II

in a saturated aliphatic monocarboxylic acid having 1 to 3 carbon atoms, using hydrogen in the presence of a hydrogenation catalyst and a sulfur compound that partly deactivates the hydrogenation catalyst.

- 25. (Currently Amended) The methodprocess according to 24, eharacterized in that wherein the saturated aliphatic acid is formic acid, acetic acid or trifluoroacetic acid.
- 26. (Currently Amended) The methodprocess according to claim 25, eharacterized in that wherein acetic acid is used in an amount of 791 to 1187 mol, preferably 890 to 1088 ml, per 1 mol of 7-ethylcamptothecin.
- 27. (Currently Amended) The methodprocess according to claim 24, eharacterized in that wherein the sulfur compound that partly deactivates the hydrogenation catalyst is dimethyl sulfoxidsulfoxide.

- 28. (Currently Amended) The methodprocess according to claim 27, eharacterized in that wherein dimethyl sulfoxide is used in an amount of 0.18 to 0.33 mol, preferably 0.23 to 0.28 ml, per 1 mol of 7-ethylcamptothecin.
- 29. (Currently Amended) The methodprocess according to claim 24, eharacterized in that wherein the hydrogenation catalyst is a noble metal.
- 30. (Currently Amended) The methodprocess according to elaim 7-claim 29, characterized in that wherein the noble metal is platinum.
- 31. (Currently Amended) The methodprocess according to elaim 8 claim 24, eharacterized-in that wherein the hydrogenation catalyst is platinum is-used on an activated carbon or aluminum oxide carrier.
- 32. (Currently Amended) The methodprocess according to elaim 9 claim 31, eharacterized in that wherein the platinum is used in an amount of 0.018 to 0.027 mol, preferably 0.020 to 0.025 mol, per 1 mol of 7-ethylcamptothecin, in the form of a hydrogenation catalyst, formed by platinum on an activated carbon with a platinum content 5%.
- 33. (Currently Amended) The methodprocess according to claim 24, eharacterized in that wherein the hydrogenation is carried out at a pressure from 0.3 to 0.7 Mpa, preferably at a pressure fro 0.4 to 0.6 Mpa.
- 34. (Currently Amended) The methodprocess according to claim 33, eharacterized in that wherein the hydrogenation is carried out at a temperature from 45 to 85°C, preferably-at-58 to 72°C.
- 35. (Currently Amended) The method<u>process</u> according to claim 33, eharacterized in that wherein the hydrogenation is carried out for 24 to 70 hours, preferably for 40 to 50 hours.
- 36. (New) The process according to claim 23 wherein the amount of iodobenzene diacetate used is 0.99 mol to 1.9 mol per mol of 7-ethyl-1,2,6,7-tetrahydrocamptothecin.

37. (New) The process according to claim 23 wherein the oxidation is carried out at a temperature ranging from 15 to 30°C.